NASDAQ:ICPT
Delisted
Intercept Pharmaceuticals Stock News
$19.00
+0 (+0%)
At Close: Feb 06, 2024
Nike's Down, but These 2 Nasdaq Stocks Fell Even Further Friday
09:44am, Friday, 30'th Sep 2022
Poor earnings and a business setback were costly for these companies.
Intercept (ICPT) Stock Gains 13% in 3 Months: Here's Why
02:46pm, Monday, 26'th Sep 2022 Zacks Investment Research
Intercept (ICPT) gains 13% in the past three months on positive regulatory and pipeline updates.
Intercept (ICPT) Stock Gains 13% in 3 Months: Here's Why
12:02pm, Monday, 26'th Sep 2022
Intercept (ICPT) gains 13% in the past three months on positive regulatory and pipeline updates.
Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday
08:04am, Thursday, 22'nd Sep 2022 Benzinga
Gainers
Stabilis Solutions, Inc. (NASDAQ: SLNG) shares climbed 71.3% to close at $8.84 after the company announced it has received authorization from the U.S. Department of Energy to export domestic
Why Adamis Pharmaceuticals Is Trading Lower By Around 44%, Here Are 46 Stocks Moving In Wednesday's Mid-Day Session
04:40pm, Wednesday, 21'st Sep 2022 Benzinga
Gainers
Stabilis Solutions, Inc. (NASDAQ: SLNG) shares jumped 108% to $10.73 after the company announced it has received authorization from the U.S. Department of Energy to export domestically produ
Intercept Pharmaceuticals Announces Summary of Key Actions in Strategic Financial Repositioning
11:30am, Wednesday, 21'st Sep 2022 GlobeNewswire Inc.
Outstanding debt reduced by 54% or $388.9 million and annual cash interest expense reduced by 58% or $13.6 million
Why Is Intercept Pharmaceuticals (ICPT) Stock Up Today?
11:01am, Wednesday, 21'st Sep 2022
Source: Postmodern Studio / Shutterstock Intercept Pharmaceuticals (NASDAQ: ICPT ) stock is on the move Wednesday after giving investors an update on how it improved its financials. A press release fr
Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology
04:45pm, Tuesday, 20'th Sep 2022 GlobeNewswire Inc.
Combined clinical trial and real-world data with six years of follow-up provides important evidence of efficacy
Regeneron (REGN)/ Alnylam Report Promising Data from NASH Study
03:29pm, Friday, 16'th Sep 2022 Zacks Investment Research
Regeneron (REGN) and its partner Alnylam announce promising data from its ongoing phase I study evaluating ALN-HSD in healthy adults and NASH patients.
Altimmune's (ALT) Data From NASH Study Fail to Impress Investors
05:28pm, Thursday, 15'th Sep 2022 Zacks Investment Research
Altimmune (ALT) reports positive top-line results from its 12-week phase I study evaluating pemvidutide in patients with non-alcoholic fatty liver disease. The results fail to impress investors.
Akero Therapeutics (AKRO) Up on Positive Data from NASH Study
05:35pm, Wednesday, 14'th Sep 2022 Zacks Investment Research
Akero Therapeutics (AKRO) reports positive top-line data from a mid-stage study evaluating its lead candidate, efruxifermin (EFX), in patients with NASH, fibrosis stage 2 or 3 (F2-F3). Stock up.
Why Is Axsome (AXSM) Up 26.9% Since Last Earnings Report?
03:30pm, Thursday, 08'th Sep 2022 Zacks Investment Research
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Intercept (ICPT) Up 15.4% Since Last Earnings Report?
03:31pm, Friday, 02'nd Sep 2022 Zacks Investment Research
Intercept (ICPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Intercept (ICPT) Up 15.4% Since Last Earnings Report?
12:48pm, Friday, 02'nd Sep 2022
Intercept (ICPT) reported earnings 30 days ago. What's next for the stock?
Implied Volatility Surging for Intercept Pharmaceuticals (ICPT) Stock Options
02:49pm, Monday, 29'th Aug 2022 Zacks Investment Research
Investors need to pay close attention to Intercept Pharmaceuticals (ICPT) stock based on the movements in the options market lately.
